HGENQ — Humanigen Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$3.10m
- $2.51m
Humanigen Inc reports results for the quarter ended in September - Earnings Summary
Brief: Humanigen Inc QTRLY Net Loss Per Common Share $0.23
Humanigen Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Humanigen Says Received Notice From Nasdaq Indicating Co Is Not In Compliance With Minimum Market Value Of Listed Securities Requirement
Brief: Humanigen Inc - On August 24, 2022, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Humanigen Reports Second Quarter 2022 Financial Results
Humanigen Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Humanigen Receives Preliminary Topline Data From NIH/NIAID Study Of Lenzilumab In ACTIV-5/BET-B
Brief: Humanigen Announces Peer-Reviewed Publication In Thorax Supporting Early Treatment Of Hospitalized Covid-19 Patients With Lenzilumab Guided By C-Reactive Protein
Brief: Humanigen Confirms Notice Received From NIAID That They Have Completed Database Lock For Big Effect Trial Of Lenzilumab
U.S. STOCKS ON THE MOVE-PROG Holdings Inc, Perion Network Ltd, Olaplex Holdings Inc
U.S. STOCKS ON THE MOVE-Ebix Inc, KLA Corp, Snowflake Inc
U.S. STOCKS ON THE MOVE-Commercial Metals Co, Intel Corp, Mastercard Inc
Humanigen rises on deal to sell COVID drug in UK post authorization
Humanigen soars as Q1 loss narrows, provides COVID-19 therapy update
Brief: Humanigen Reports First Quarter 2022 Financial Results
Brief: Humanigen Announces Peer-Reviewed Publication Demonstrating The Potential Clinical, Economic Benefits Of Lenzilumab From The Perspective Of The NHS
Brief: Humanigen Files Prospectus Related To Offering Of Common Stock Up To $75 Mln
Brief: Humanigen Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing